Wall Street brokerages expect that CareDx Inc (NASDAQ:CDNA) will report earnings of ($0.15) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for CareDx’s earnings. CareDx reported earnings of ($0.13) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 15.4%. The company is expected to report its next quarterly earnings results after the market closes on Thursday, March 22nd.
Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for CareDx.
Several research analysts have recently commented on the stock. ValuEngine raised shares of CareDx from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of CareDx in a report on Wednesday, January 31st. Finally, Zacks Investment Research raised shares of CareDx from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Wednesday, January 10th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $8.65.
Shares of CDNA stock traded down $0.09 on Monday, hitting $5.70. 706,192 shares of the stock traded hands, compared to its average volume of 201,141. CareDx has a 12 month low of $0.76 and a 12 month high of $7.98. The company has a market capitalization of $165.62, a PE ratio of -3.15 and a beta of 0.72. The company has a debt-to-equity ratio of -124.53, a current ratio of 0.55 and a quick ratio of 0.35.
Several hedge funds and other institutional investors have recently bought and sold shares of CDNA. Fred Alger Management Inc. acquired a new stake in shares of CareDx during the 4th quarter worth approximately $9,089,000. Perceptive Advisors LLC acquired a new stake in shares of CareDx during the 4th quarter worth approximately $7,639,000. Gagnon Advisors LLC boosted its position in shares of CareDx by 26,929.4% during the 4th quarter. Gagnon Advisors LLC now owns 955,758 shares of the company’s stock worth $7,015,000 after acquiring an additional 952,222 shares in the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of CareDx during the 4th quarter worth approximately $6,753,000. Finally, Park West Asset Management LLC acquired a new stake in shares of CareDx during the 4th quarter worth approximately $5,944,000. Institutional investors and hedge funds own 52.35% of the company’s stock.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.